3-[(2,2,3,3,4,4,5,5-2H8)cyclopentyl]-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile

• ChemBase ID: 177661
• Molecular Formular: C17H18N6
• Molecular Mass: 306.36502
• Monoisotopic Mass: 306.15929461
• SMILES: c12c(ncnc1c1cn(nc1)C(C1CCCC1)CC#N)[nH]cc2
• Canonical SMILES: N#CCC(n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1
• InChI: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)
• InChIKey: HFNKQEVNSGCOJV-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 3-[(2,2,3,3,4,4,5,5-^2H₈)cyclopentyl]-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile
• IUPAC Traditional name: 3-[(2,2,3,3,4,4,5,5-^2H₈)cyclopentyl]-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}pyrazol-1-yl)propanenitrile
• Synonyms: β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INCB 018424-d8; rac-Ruxolitinib-d8

Database IDs

• PubChem SID: 164233571
• PubChem CID: 71752146

CALCULATED PROPERTIES

• Acid pKa: 13.89365
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 2.1799238
• LogD (pH = 7.4): 2.4738674
• Log P: 2.4793217
• Molar Refractivity: 98.0065 cm^3
• Polarizability: 34.707798 Å^3
• Polar Surface Area: 83.18 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

DETAILS

Toronto Research Chemicals - R701998

Labelled racemic analogue of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.

REFERENCES

• Shilling, A.D. et al.: Drug Metab. Disp., 38, 2023 (2010)
• Mesa, R.A.: IDrugs, 13, 394 (2010)
• Campas-Moya, C.: Drugs Fut., 35, 457 (2010)